Cochrane Database of Systematic Reviews
September 12, 2021
Rebecca L. Dean, Claudia C. Hurducas, Keith Hawton et al.
97 citations
BACKGROUND Many studies have recently been conducted to assess the antidepressant efficacy of glutamate modification in mood disorders. This is an update of a review first published in 2015 focusing on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor...
Mindfulness
September 11, 2021
Dave Parsons, P. Gardner, Sharon Parry et al.
High rates of depression, anxiety and stress are reported in tertiary health students. Mindfulness-based programs have been included in the training of health students to help them manage depression, anxiety and stress; however, to date, there has been no review of best practice implementation of mindfulness for health students. The aim of this review was to evaluate the outcomes of...
General Hospital Psychiatry
September 11, 2021
Jennifer Huberty, Megan E. Puzia, Jeni Green et al.
76 citations
OBJECTIVE: The objective of this study was to 1) determine the effects of a meditation app on depression and anxiety in adults with sleep disturbance, and 2) explore the potential mediating effects of fatigue, daytime sleepiness, and pre-sleep arousal on the relationship between use of the meditation app and changes in depression and anxiety. METHODS: Participants were 239 adults with elevated...
Revista Portuguesa de Psiquiatria e Saúde Mental
September 8, 2021
Gonçalo Cotovio, Ana Maia, Ana Velosa et al.
.
Frontiers in Psychology
September 3, 2021
Niklas Bergmann, Eric Hahn, Inge Hahne et al.
Background: Schizophrenia spectrum disorders (SSD) are frequently accompanied by comorbid depressive and anxiety symptoms, as well as impaired quality of life (QoL). A growing body of evidence has demonstrated the relevance of mindfulness for SSD in recent years. The study examined the association between mindfulness, depression, anxiety, and QoL.Materials and Methods: A total of 83...
Translational Psychiatry
September 3, 2021
Chao Huang, Yuanyuan Wang, Zifeng Wu et al.
29 citations
Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but its underlying molecular mechanisms remain unclear. Recent studies have emerged microRNAs as important modulators for depression treatment. In this study, we report that miR-98-5p is downregulated in the prefrontal cortex and hippocampus of mice subjected to chronic social stress, while overexpressing it by...
Brain Stimulation
September 1, 2021
M. Davila, A. Hess, Ananya Louviere et al.
Background: Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulatory technique approved for the treatment of major https://doi.org/10.1016/j.brs.2021.07.023 depressive disorder (MDD) impacting orbital frontal cortex functioning. We have previously identified significant changes in ratings for several standard metrics for depression, anxiety, pain and ADHD after 6 weeks of...
Saudi Journal of Biological Sciences
September 1, 2021
Atheer M. Mohammed, Ibrahim A. Khardali, Magbool E. Oraiby et al.
7 citations
Cannabis is an annual herbaceous plant sometimes grown for decoration and used as bird food that looks like flax. The study wanted to determine if a Cannabis extract may have an effect on how anxious and depressed the female mice behaved. forty healthy female mice were divided into four groups. Tap water was administered to the first group (control). Ethanol was administered to second group...
Journal of Psychosocial Nursing and Mental Health Services
August 30, 2021
Karan S Kverno, Emma Mangano
121 citations
Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered to have treatment-resistant depression (TRD). Because the odds of remission decrease with every subsequent medication trial, it is important for clinicians to understand the characteristics and risk factors for TRD,...
Cureus
August 21, 2021
Alisha Sapkota, Hajra Khurshid, Israa A Qureshi et al.
44 citations
Intranasal form of esketamine, the S-enantiomer of racemic ketamine, was approved by the US FDA in 2019 for treatment-resistant depression (TRD) in adults. Since intranasal esketamine is a newly approved drug with a novel mechanism of action, much still remains unknown in regard to its use in TRD. The objective of this study is to systematically review the latest existing evidence on intranasal...